Business
BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo
6 out of 20 patients treated with NE3107 experienced a morning “on state” while 0 out of 19 placebo-treated patients had an “on” (p=0.02) CARSON CITY, Nev.,
About this update from Biovie Inc.
[{"type":"text","content":"6 out of 20 patients treated with NE3107 experienced a morning “on state” while 0 out of 19 placebo-treated patients had an “on” (p=0.02)\nCARSON CITY, Nev., March 06, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced additional preliminary findings from its Parkinson’s Disease (PD) Phase 2 trial. The preliminary findings show that significantly more patients treated with the Company’s drug, NE3107, were assessed as being in the “ON” state in the morning after withholding their usual standard of care (SOC) for at least 8 hours before taking their usual morning Parkinson’s medications, compared to patients on SOC alone plus placebo (p","length":1013,"tagName":"div"}]